AeroLeads people directory · profile
Ron Squarer Email & Phone Number
Board Member
at
Nuvalent, Inc.
1 work email found
@adctherapeutics.com
12 phones found area 303, 917, 847, 914, 270, 423, 720, 646, and 224
LinkedIn matched
✓ Verified July 2026
4 data sources
Profile completeness 100%
Current company
Role
Board Member
Location
Boulder, Colorado, United States
Company size
Who is Ron Squarer? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Ron Squarer is listed as Board Member at Nuvalent, Inc., a with 208 employees, based in Boulder, Colorado, United States. AeroLeads shows a work email signal at adctherapeutics.com, phone signal with area code 303, 917, 847, 914, 270, 423, 720, 646, 224, and a matched LinkedIn profile for Ron Squarer.
Ron Squarer previously worked as Board Chair, ADC Therapeutics SA at Adc Therapeutics and Member Board Of Directors at Travere Therapeutics. Ron Squarer holds Mba, Finance, Strategy, Marketing from Northwestern University - Kellogg School Of Management.
Company email context
Email format at Nuvalent, Inc.
This section adds company-level context without repeating Ron Squarer's masked contact details.
{first}.{last}@adctherapeutics.com
86% confidence
AeroLeads found 1 current-domain work email signal for Ron Squarer. Compare company email patterns before reaching out.
Profile bio
About Ron Squarer
Ron Squarer served as Board Chair of Deciphera Pharmaceuticals Inc. (the makers of Qinlock® and vimseltinib) through its acquisition by Ono Pharmaceuticals for ~$2.5 billion (a 75% premium) in June 2024 and was the former CEO of Array Biopharma through its acquisition by Pfizer Inc. for $11.8 billion in August 2019 following the successful launch of the cancer treatments Braftovi® and Mektovi®. During his tenure, Array’s valuation grew ~40-fold through execution across research, development, and commercialization focused in the Oncology area. Array Biopharma’s research team is also recognized for inventing Vitrakvi®, Koselugo®, Tukysa®, Retevmo®, Krazati™, and ipatasertib/AKT, among other molecules. Mr. Squarer is currently the Board Chair of ADC Therapeutics (the makers of Zynlonta®) and is a Board member at Travere Therapeutics Inc. (the makers of Filspari®). Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc. (now Pfizer Inc.), a global pharmaceutical and medical device company. As Chief Commercial Officer, he delivered $4 billion in worldwide annual revenue. He joined Hospira from Mayne Pharma, where he served as SVP, Global Corporate and Business Development, when Mayne was acquired by Hospira for over $2 billion. Before Mayne Pharma, he held leadership roles at Pfizer, Inc. (including in Oncology) and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. Mr. Squarer earned an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.
Listed skills include Pharmaceutical Industry, Oncology, Commercialization, Strategy, and 19 others.
Current workplace
Ron Squarer's current company
Company context helps verify the profile and gives searchers a useful next step.
Nuvalent, Inc.
11 roles · 35 years
Ron Squarer work experience
A career timeline built from the work history available for this profile.
Board Chair, Adc Therapeutics Sa
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. https://www.zynlonta.com
Member Board Of Directors
At Travere Therapeutics Inc. (NASDAQ: TVTX), we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. FILSPARI (sparsentan) is a once-daily, oral medication designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II) and is the first and only non-immunosuppressive therapy approved for the treatment of this condition. https://filspari.com/igan/
Board Chair
Jun 2023 - Jun 2024
Member Board Of Directors
Deciphera was acquired by Ono Pharmaceuticals for ~$2.5 billion (a 75% premium) in June 2024. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. The company leverages a proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing product candidates in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK® is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Norway, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. The company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for a second product, vimseltinib, for potential use in patients with tenosynovial giant cell tumors.
Dec 2019 - Jun 2023
Chief Executive Officer
Array Biopharma Inc. was acquired by Pfizer Inc. for $11.8 billion in August 2019. Array was a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi® (larotrectinib, partnered with Loxo Oncology) is approved in the United States and Ganovo® (danoprevir, partnered with Roche) is approved in China.
Apr 2012 - Aug 2019
Chief Commercial Officer
- Hospira sold to Pfizer Inc. for $17 Billion in 2015.- Delivered ~$4 billion in Pharmaceutical and Medical Device sales.- Ran world leading contract manufacturing business (#1 globally in vials).- Led >2,000 person global commercial organization across four regions (US, Canada/Latin America, Europe/Middle East/Africa and Asia Pacific) driving consistent annual growth.- Doubled global proprietary product sales in two years.
Jan 2010 - 2012
Senior Vice President, Global Marketing And Corporate Development
- Led global product marketing, new product commercialization, M&A, licensing, venture investing, P&Ls for new emerging businesses, corporate planning and portfolio management.- Signed >40 deals in total including four company acquisitions and four business disposals.
Jan 2007 - Jan 2010
Senior Vice President, Global Corporate & Business Development
- Sold to Hospira (now Pfizer Inc.) for $2.1 Billion in 2007.- Global Oncology focused Mergers, Acquisitions, Licensing, and Collaborations.
2006 - 2007
~1 yr
Commercial Development Leader, Oncology New Product Development And Licensing
Jan 2001 - 2006
Country Manager, Sales And Marketing, Business Development, Product Manager
Various US and European Roles
1992 - 2001
~9 yrs
2 education records
Ron Squarer education
Mba, Finance, Strategy, Marketing
Northwestern University - Kellogg School Of Management
Bs/Ba, Biochemisty/Political Science
University Of California, Berkeley
FAQ
Frequently asked questions about Ron Squarer
Quick answers generated from the profile data available on this page.
What company does Ron Squarer work for?
Ron Squarer works for Nuvalent, Inc..
What is Ron Squarer's role at Nuvalent, Inc.?
Ron Squarer is listed as Board Member at Nuvalent, Inc..
What is Ron Squarer's email address?
AeroLeads has found 1 work email signal at @adctherapeutics.com for Ron Squarer at Nuvalent, Inc..
What is Ron Squarer's phone number?
AeroLeads has found 12 phone signal(s) with area code 303, 917, 847, 914, 270, 423, 720, 646, 224 for Ron Squarer at Nuvalent, Inc..
Where is Ron Squarer based?
Ron Squarer is based in Boulder, Colorado, United States while working with Nuvalent, Inc..
What companies has Ron Squarer worked for?
Ron Squarer has worked for Nuvalent, Inc., Adc Therapeutics, Travere Therapeutics, Deciphera Pharmaceuticals, and Array Biopharma Inc..
How can I contact Ron Squarer?
You can use AeroLeads to view verified contact signals for Ron Squarer at Nuvalent, Inc., including work email, phone, and LinkedIn data when available.
What schools did Ron Squarer attend?
Ron Squarer holds Mba, Finance, Strategy, Marketing from Northwestern University - Kellogg School Of Management.
What skills is Ron Squarer known for?
Ron Squarer is listed with skills including Pharmaceutical Industry, Oncology, Commercialization, Strategy, Medical Devices, Biotechnology, Infectious Diseases, and Clinical Trials.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial